NCT00345501View on ClinicalTrials.gov

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

July 31, 2007

Conditions
Renal Insufficiency, ChronicCoronary AngiographyAngioplasty, Transluminal, Percutaneous Coronary
Interventions
DRUG

Iloprost

Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end

DRUG

Placebo

Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end

Trial Locations (1)

17674

Onassis Cardiac Surgery Centre, Athens

All Listed Sponsors
lead

Onassis Cardiac Surgery Centre

OTHER

NCT00345501 - Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention | Biotech Hunter | Biotech Hunter